Jazz Pharmaceuticals Completes Study on Promising HER2 Cancer Treatment

Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.

Jazz Pharmaceuticals has recently completed a clinical study titled ‘A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer.’ The study aimed to evaluate the safety and effectiveness of combining zanidatamab with evorpacept (ALX148) in treating patients with advanced HER2-expressing cancers. This study is significant as it explores new treatment avenues for cancers that express the HER2 protein, potentially offering new hope for patients with limited options.

The study tested two drugs: zanidatamab and evorpacept, both administered intravenously. Zanidatamab is designed to target and bind to the HER2 protein, while evorpacept is intended to enhance the immune system’s response against cancer cells.

The study was interventional, using a non-randomized, single-group assignment. It was an open-label study, meaning both researchers and participants knew which treatment was being administered. The primary purpose was treatment-focused, aiming to assess the combination’s safety and antitumor activity.

Key dates for the study include its start on August 23, 2021, and its completion on October 14, 2025. These dates are crucial for understanding the study’s timeline and the progression of its phases, which can impact regulatory reviews and potential market entry.

This update could influence Jazz Pharmaceuticals’ stock performance positively, as successful results may lead to new treatment approvals, enhancing the company’s portfolio. Investors will be keenly watching for outcomes that could differentiate Jazz from competitors in the oncology sector, especially in the growing market for HER2-targeted therapies.

The study is now completed, with further details available on the ClinicalTrials portal.